Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic UFT + cyclophosphamide + celecoxib in pretreated advanced gastrointestinal malignancies
2007-000065-38Phase 2Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- May 2007
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur + uracil, cyclophosphamide and celecoxib in colorectal cancer (CRC), pancreatic cancer (PC), gastric cancer (GC) and 3 more, sponsored by Azienda USL Toscana Nord Ovest. Primary endpoint: Percentage of patients free of progression at 2 months. Started May 2007; status: active.
02
Drugs
tegafur + uracilcyclophosphamidecelecoxib
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)gastric cancer (GC)hepatocellular carcinoma (HCC)biliary cancer
Beyond the preview
Go deeper on 2007-000065-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000065-38.